Comparative Pharmacology
Head-to-head clinical analysis: ASTELIN versus ASTEPRO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ASTELIN versus ASTEPRO.
ASTELIN vs ASTEPRO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Azelastine, a phthalazinone derivative, exerts its effects by competitively inhibiting histamine H1-receptors, stabilizing mast cells, and reducing the release of inflammatory mediators. It also has anti-allergic properties including inhibition of leukotriene synthesis and suppression of eosinophil chemotaxis.
Selective histamine H1 receptor antagonist; inhibits histamine release from mast cells and basophils, thereby reducing allergic symptoms.
1 spray (137 mcg) per nostril twice daily (total daily dose: 548 mcg).
One 0.15% ophthalmic solution drop instilled into the affected eye(s) twice daily (approximately every 8 to 12 hours).
None Documented
None Documented
The terminal elimination half-life of azelastine (active ingredient) is approximately 22 hours, supporting twice-daily dosing.
Terminal elimination half-life is approximately 28–36 hours. Clinical context: supports once-daily dosing; steady state reached after 5–7 days.
Renal excretion accounts for approximately 75% of the administered dose, with about 10% as unchanged drug. Fecal excretion is about 20%.
Primarily renal elimination: approximately 70% of an oral dose is excreted unchanged in urine, with <10% as metabolites. Fecal elimination accounts for <20%.
Category C
Category C
Antihistamine (Nasal)
Antihistamine (Nasal)